ICG-Cisplatin Self-Assembled Nanoprobes for Near-Infrared-Il Fluorescence Imaging-Guided Liver Resection
This prospective, single-arm exploratory study evaluates the feasibility and safety of a novel ICG-Cisplatin self-assembled nanoprobe (NIR-II NanoM) for fluorescence-guided surgery in patients with Hepatocellular Carcinoma (HCC). Participants will receive a transarterial injection of the nanoprobe mixed with lipiodol prior to surgery. During the subsequent laparoscopic anatomic hepatectomy, surgeons will utilize a Near-Infrared II (NIR-II) imaging system to visualize tumor boundaries and liver segments for precise resection.
• Age 18-75 years.
• First diagnosis of Hepatocellular Carcinoma (HCC) (non-recurrent).
• Single tumor with diameter ≤ 5 cm.
• Assessed as resectable by more than 2 senior liver surgeons (experience \>10 years, \>500 hepatectomies).
• No distant metastasis on preoperative chest CT and abdominal contrast-enhanced CT.
• Child-Pugh Class A liver function.
• Patient or legal guardian able to understand the study and sign informed consent.